Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MB 101 - Mustang Bio

Drug Profile

MB 101 - Mustang Bio

Alternative Names: Anti-IL13Rα2-CAR-4-1BB/BBzeta-CD19t-expressing T-cells; IL13(EQ)BBzeta/CD19t+ TCM-enriched T Cells; IL13Ralpha2-CAR T Cells; IL13Rα2 CAR T; IL13Rα2-specific CAR-T cells - Mustang Bio; IL13Rα2-targeted CAR T cell therapy; MB-101 - Mustang Bio

Latest Information Update: 12 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator City of Hope National Medical Center
  • Developer City of Hope National Medical Center; National Cancer Institute (USA)
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Brain cancer; Glioblastoma; Meningeal carcinomatosis

Most Recent Events

  • 12 Mar 2024 MB 101 is in phase-I clinical trials in Brain cancer (Combination therapy, In children, In adults, In adolescents, Recurrent, Second-line therapy or greater) in USA (Intraventricular) (NCT04510051)
  • 12 Mar 2024 MB 101 is still in phase I trial for Glioblastoma(Combination therapy, Monotherapy, Recurrent, Second-line therapy or greater) in USA (Intratumoural) (Intraventricualr) (NCT04003649) (Mustang Bio pipeline, March 2024)
  • 12 Mar 2024 MB 101 is still in phase-I clinical trials in Meningeal carcinomatosis (Adjuvant therapy, Second-line therapy or greater) in USA (Intraventricular) (NCT04661384)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top